LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours

LENZ Therapeutics, Inc.

Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).
Rapid onset: 71% achieved ≥3-line improvement at 30 minutes; long duration: 40% at 10 hours.
No serious treatment-related adverse events in >30,000 treatment days across three trials.
LNZ100 selected as lead candidate; company plans NDA submission to FDA in mid-2024.
Patient survey: 90% reported near vision improvement; 75% would continue use post-study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.